膦甲酸（PFA，膦甲酸钠）的抗病毒作用。 - Suppr

Suppr

超能文献

Antiviral effects of phosphonoformate (PFA, foscarnet sodium).

作者信息

Oberg B

出版信息

Pharmacol Ther. 1982;19(3):387-415. doi: 10.1016/0163-7258(82)90074-2.

DOI:10.1016/0163-7258(82)90074-2

PMID:6201932

Abstract

摘要

相似文献

Antiviral effects of phosphonoformate (PFA, foscarnet sodium).

Pharmacol Ther. 1982;19(3):387-415. doi: 10.1016/0163-7258(82)90074-2.

Antiviral effects of phosphonoformate (PFA, foscarnet sodium).

Pharmacol Ther. 1989;40(2):213-85. doi: 10.1016/0163-7258(89)90097-1.

The antiherpesvirus action of phosphonoacetate.

Pharmacol Ther. 1979;4(1):231-43. doi: 10.1016/0163-7258(79)90021-4.

Inhibition of HTLV-III/LAV replication by foscarnet.

Biochem Pharmacol. 1985 Nov 15;34(22):4075-9. doi: 10.1016/0006-2952(85)90392-2.

Trisodium phosphonoformate, a new antiviral compound.

Science. 1978 Sep 1;201(4358):819-21. doi: 10.1126/science.210500.

Mechanism of action of foscarnet against viral polymerases.

Am J Med. 1992 Feb 14;92(2A):3S-7S. doi: 10.1016/0002-9343(92)90329-a.

Phosphonoformate inhibits reverse transcriptase.

J Gen Virol. 1979 Nov;45(2):273-81. doi: 10.1099/0022-1317-45-2-273.

In vitro inhibition of Herpesvirus sylvilagus by phosphonoacetic acid and phosphonoformate.

Arch Virol. 1980;66(3):261-4. doi: 10.1007/BF01314739.

In vitro inhibition of human herpesvirus-6 by phosphonoformate.

J Virol Methods. 1988 Sep;21(1-4):301-4. doi: 10.1016/0166-0934(88)90075-4.

Mechanism of inhibition of Epstein-Barr virus replication by phosphonoformic acid.

Virology. 1981 Oct 15;114(1):52-9. doi: 10.1016/0042-6822(81)90251-8.

引用本文的文献

Recent advances in natural and synthetic phosphonate therapeutics.

Curr Opin Microbiol. 2025 Jul 11;87:102630. doi: 10.1016/j.mib.2025.102630.

Chapter 12. Antiviral Agents.

Annu Rep Med Chem. 1984;19:117-126. doi: 10.1016/S0065-7743(08)60688-0. Epub 2008 Apr 10.

Chapter 9 Infections caused by rubella, reoviridae, retro, Norwalk and ronaviruses.

Perspect Med Virol. 1985;1:405-444. doi: 10.1016/S0168-7069(08)70017-X. Epub 2008 May 29.

Chapter 3 Antiviral drugs: general considerations.

Perspect Med Virol. 1985;1:93-126. doi: 10.1016/S0168-7069(08)70011-9. Epub 2008 May 29.

Substrates and inhibitors of phosphate transporters: from experimental tools to pathophysiological relevance.

Pflugers Arch. 2019 Jan;471(1):53-65. doi: 10.1007/s00424-018-2241-x. Epub 2018 Dec 7.

Derivatives of mesoxalic acid block translocation of HIV-1 reverse transcriptase.

J Biol Chem. 2015 Jan 16;290(3):1474-84. doi: 10.1074/jbc.M114.614305. Epub 2014 Oct 29.

Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B.

Viruses. 2010 Oct;2(10):2169-2195. doi: 10.3390/v2102169. Epub 2010 Sep 28.

Mechanism of hepatitis C virus RNA polymerase inhibition with dihydroxypyrimidines.

Antimicrob Agents Chemother. 2010 Mar;54(3):977-83. doi: 10.1128/AAC.01216-09. Epub 2009 Dec 22.

Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet.

J Virol. 2006 Feb;80(3):1440-50. doi: 10.1128/JVI.80.3.1440-1450.2006.

Efficacies of topical formulations of foscarnet and acyclovir and of 5-percent acyclovir ointment (Zovirax) in a murine model of cutaneous herpes simplex virus type 1 infection.

Antimicrob Agents Chemother. 2000 Jan;44(1):30-8. doi: 10.1128/AAC.44.1.30-38.2000.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Antiviral effects of phosphonoformate (PFA, foscarnet sodium).

Pharmacol Ther. 1982;19(3):387-415. doi: 10.1016/0163-7258(82)90074-2.

Antiviral effects of phosphonoformate (PFA, foscarnet sodium).

Pharmacol Ther. 1989;40(2):213-85. doi: 10.1016/0163-7258(89)90097-1.

The antiherpesvirus action of phosphonoacetate.

Pharmacol Ther. 1979;4(1):231-43. doi: 10.1016/0163-7258(79)90021-4.

Inhibition of HTLV-III/LAV replication by foscarnet.

Biochem Pharmacol. 1985 Nov 15;34(22):4075-9. doi: 10.1016/0006-2952(85)90392-2.

Trisodium phosphonoformate, a new antiviral compound.

Science. 1978 Sep 1;201(4358):819-21. doi: 10.1126/science.210500.

Mechanism of action of foscarnet against viral polymerases.

Am J Med. 1992 Feb 14;92(2A):3S-7S. doi: 10.1016/0002-9343(92)90329-a.

Phosphonoformate inhibits reverse transcriptase.

J Gen Virol. 1979 Nov;45(2):273-81. doi: 10.1099/0022-1317-45-2-273.

In vitro inhibition of Herpesvirus sylvilagus by phosphonoacetic acid and phosphonoformate.

Arch Virol. 1980;66(3):261-4. doi: 10.1007/BF01314739.

In vitro inhibition of human herpesvirus-6 by phosphonoformate.

J Virol Methods. 1988 Sep;21(1-4):301-4. doi: 10.1016/0166-0934(88)90075-4.

Mechanism of inhibition of Epstein-Barr virus replication by phosphonoformic acid.

Virology. 1981 Oct 15;114(1):52-9. doi: 10.1016/0042-6822(81)90251-8.

引用本文的文献

Recent advances in natural and synthetic phosphonate therapeutics.

Curr Opin Microbiol. 2025 Jul 11;87:102630. doi: 10.1016/j.mib.2025.102630.

Chapter 12. Antiviral Agents.

Annu Rep Med Chem. 1984;19:117-126. doi: 10.1016/S0065-7743(08)60688-0. Epub 2008 Apr 10.

Chapter 9 Infections caused by rubella, reoviridae, retro, Norwalk and ronaviruses.

Perspect Med Virol. 1985;1:405-444. doi: 10.1016/S0168-7069(08)70017-X. Epub 2008 May 29.

Chapter 3 Antiviral drugs: general considerations.

Perspect Med Virol. 1985;1:93-126. doi: 10.1016/S0168-7069(08)70011-9. Epub 2008 May 29.

Substrates and inhibitors of phosphate transporters: from experimental tools to pathophysiological relevance.

Pflugers Arch. 2019 Jan;471(1):53-65. doi: 10.1007/s00424-018-2241-x. Epub 2018 Dec 7.

Derivatives of mesoxalic acid block translocation of HIV-1 reverse transcriptase.

J Biol Chem. 2015 Jan 16;290(3):1474-84. doi: 10.1074/jbc.M114.614305. Epub 2014 Oct 29.

Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B.

Viruses. 2010 Oct;2(10):2169-2195. doi: 10.3390/v2102169. Epub 2010 Sep 28.

Mechanism of hepatitis C virus RNA polymerase inhibition with dihydroxypyrimidines.

Antimicrob Agents Chemother. 2010 Mar;54(3):977-83. doi: 10.1128/AAC.01216-09. Epub 2009 Dec 22.

Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet.

J Virol. 2006 Feb;80(3):1440-50. doi: 10.1128/JVI.80.3.1440-1450.2006.

Efficacies of topical formulations of foscarnet and acyclovir and of 5-percent acyclovir ointment (Zovirax) in a murine model of cutaneous herpes simplex virus type 1 infection.

Antimicrob Agents Chemother. 2000 Jan;44(1):30-8. doi: 10.1128/AAC.44.1.30-38.2000.